Research archive.
The complete, chronological record of Clinaptis analysis. Every note is full text, connected to the company files it informs.
Showing 38 of 38 notes · 32 companies · 6 months · May 2026—Oct 2026
Dyne (DYN): HARBOR Cut the Price. Didn’t Lower the Bar for ACHIEVE-REC DM1
Novartis Phase 3 HARBOR miss hit Dyne’s valuation though we estimate $1.5B NPV is still attributable to DM1. We remain cautious (41% odds) into Q1 2027 Achieve-REC readout of Z-basivarsen.
- XBI
XBI Short Interest: Still Not Covering [Aug 15 to Sep 15]
The $1–5B bear book kept adding through an August rally and a September decline: builds outran covers 24 to 17, then 27 to 7.
Eli Lilly’s Eloralintide + Tirzepatide: Stronger Parts, Not Synergy in Diabetes
Lilly’s 10-arm eloralintide + tirzepatide Phase 2 in type 2 diabetes reads out at EASD. Our bar: 12–14% placebo-adj. weight loss at go-forward dose; <11% disappoints. GI burden decides market.
Praxis (PRAX): EMERALD Doesn't Need Another 53% Seizure Reduction
EMERALD needs roughly 22.5% placebo-adjusted efficacy across broad DEE, not another EMBOLD-like 53%; who responds and how the primary analysis measures the mixture determine the franchise value.
Viking Therapeutics (VKTX): The Schedule Held; the Price Ran Ahead
VK2735's maintenance data strengthen the subcutaneous thesis. We assess the value added against VKTX's $1.25 billion rally.
Agios (AGIO): Mitapivat in Sickle Cell Disease — REIGNITE Is Not the Hard Part
Our work supports ~72% predictive PoS for Phase 3 REIGNITE. The harder question is whether mitapivat can capture enough SCD share to justify $33/sh.
Rhythm (RYTM): The Price of a Strong Rare-Obesity Launch
The acquired-HO launch is strong, but our cohort model implies ~$63 per share at Base and shows how much patient capture, persistence and post-2034 durability the ~$8B valuation already requires.
Lp(a) After the First Failure: Repricing OCEAN(a)
The dual endpoint miss puts null Lp(a) biology near 19% and reprices OCEAN(a) from 87.9% pre-HORIZON to ~65–72% statistical success.
- XBI
XBI Short Interest: The Approval They Shorted Anyway
In 1H August, 38 of 60 core XBI names added to shorts while aggregate exposure rose just 0.7%—broad builds offset by a few catalyst-driven covers.
Definium, Psychedelics & the Price of Replication in Anxiety (GAD)
Phase 3 PANORAMA in GAD is overwhelmingly likely to succeed statistically. But HAM-A efficacy magnitude matters non-linearly: the value curve steepens around the ~4-point differentiation threshold.
Corbus (CRBP): CANYON-1 and the Twenty-Year Search for a Peripheral CB1 Window
The bar is ≥5% Week-12 weight loss without a CNS signal. Clear it, and CRB-913 becomes an investable peripheral-CB1 asset worth ~$16.5/share versus ~$11 today.
Annexon: ARCHER II Is More Than a Replication Bet in GA
ARCHER II can survive heavy regression of the Phase 2 GA effect — RR ~0.5–0.6 still leaves a viable Phase 3, with replicated visual functional benefit offering genuine differentiation in GA
Kodiak's DAYBREAK: Likely to Work, Less Likely to Matter
Non-inferiority remains the base case (~63%) — but the pass is more likely to be commercially thin than differentiated, and that is what the stock trades on.
- XBI
XBI: What Survived July's Short Retreat
XBI Short Interest Monitor · $1–5B cohort · July 31, 2026 settlement
Celldex: A Positive CSU Readout May Not Be Enough
The p-value looks de-risked. Valuation hinges on whether complete response (CR) looks more like remibrutinib (~28–31%) or clears Xolair’s historical ~34–44% range.
Praxis: Odds Favor Ulixacaltamide Approval in ET, but…
The regulatory case looks settled. The commercial case does not: patients × price × persistence now decide whether today's valuation holds.
Structure Therapeutics: Is Aleniglipron Really Best-in-Class?
Aleniglipron's 16.3% WL headline restates to ~10–11pp on the basis FDA now requires — a real edge in. oral GLP-1 class, not an established best-in-class gap.
Viking Therapeutics (VKTX): Repricing VK2735
Separating the SC valuation floor from the unresolved oral opportunity through a reverse-solve valuation framework and a ~608,000-patient crossover analysis.
Acadia's Alzheimer's Psychosis Bet: Direction Is Priced, Resolution Is Not
We're constructive into Sep/Oct: ~70–80% odds of success, and we like the setup — the alpha's in the magnitude: fade a thin print, add on a strong one.
Lean Mass: Selectivity Is the Trap
Selectivity makes apitegromab's lean-mass result (1.9 kg preserved vs. placebo) the cleanest in obesity — and the why exactly why it hasn't proven mass becomes function.
BIIB Alzheimer’s: CELIA Validated Tau, Not the Clinical Effect Size
The reported 26% slowing likely overstates the underlying effect. That does not mean Biogen chose the wrong dose.
- XBI
Where Bears Are Still Building In XBI
Why crowded shorts have already priced the bear case — and where the marginal short is actually arriving.
MPLT: Antipsychotic Efficacy Is the Floor. Tolerability Is the Trade Into Ph2 Readout
Cobenfy proved dual M1/M4 agonism works. Ph2 ZEPHYR's job is showing whether ML-007C-MA's PK-tuned tolerability edge is real — which is why the AE table, not the PANSS table, carries the real signal.
- BMYJNJ
Milvexian: AF and Stroke Indications Should Be Valued Separately
A quantitative reconstruction of BMS/J&J's Phase 3 dose-selection framework, using PK/PD modeling to independently estimate each indication's probability of success.
AMLX: Ph3 PBH Readout Less Binary Than It Looks
Three independent statistical frameworks suggest 3Q26 LUCIDITY readout is materially more derisked than prevailing investor confidence implies.
uniQure’s AMT-130: The FDA Changed Its Mind. The Data Didn’t.
Projecting Four-Year cUHDRS and TFC Outcomes Ahead of AMT-130’s Q3 2026 BLA, Confirmatory Trial, and Commercial Launch in Huntington's Disease (HD)
When 45% Isn't Enough: Rethinking Disease Modification in IgAN
Reviewing Vera's Atacicept & Why the Next IgAN Winners Will Be Decided by Residual Disease Burden.
IONS Drew First Blood. SHASTA-3/4 Is Arrowhead’s Turn
Tryngolza’s approval changes the question ahead of SHASTA-3/4. The Street will focus on headline TG reduction; we think the real readout is threshold crossing below 500 mg/dL.
- Cross-sector
The Rise of Mini-Pharma: Why Commercial Concentration Is Replacing Platform Breadth
Concentration, commercial proof, and the rise of biotech’s new operating model.
Axsome (AXSM): $250 Is the Problem
Auvelity is a real franchise. The ADA launch is real optionality. Neither justifies $250.
Orexin and Narcolepsy
What the first orexin agonist approval in Narcolepsy Type I (NTI) actually validates.
GLP-1s Solved Efficacy. They Haven't Solved Obesity
The two-leak problem in the obesity treatment funnel — and what oral drugs can and cannot fix.
The MASH Bridge Trap
Why Madrigal's Rezdiffra Market Is Smaller Than the Model
Pancreatic Cancer Had No Druggable Target. Now It Does
Daraxonrasib in 2L PDAC: When the Data Actually Deliver
Retatrutide’s 28%: The PCSK9 Mistake
Why Superior Efficacy Doesn't Always Win the Market
- XBI
XBI 2026: What the Tape Is Rewarding vs. Punishing
Why 2026 Became a Market for Visibility, Reinforcement, and Shorter Timelines
Obesity: Leaders De-risked, Debate Shifting Toward Market Structure
Obesity Is Evolving From a Drug Category Into Metabolic Infrastructure
- Cross-sector
Functional Endpoints and the New CNS Market Structure
Functional Endpoints, Persistence Economics, and Signal Interpretation in Modern Neuropsychiatry
No matching notes